Due to COVID-19 the clinical trial industry has been adopting advanced clinical trial technology at warp speed, but what does this mean for the future? What is a sustainable approach to ensure the industry does not face the same challenges and delays should we be impacted by another pandemic or global crisis? In this podcast we sit down with Mary Mattes, Senior Vice President of Global Operations at Synteract to discuss decentralization of clinical trials and a hybrid model.
Approximately 39.5% of all men and women will be diagnosed with cancer at some point during their lifetimes, and yet only 8% of oncology...
Patients are no longer passive research subjects, but rather being integrated into the research process from the start. Patient advocates help with such integrations,...
Australia and New Zealand have not been impacted as much as North America and the EU with regards to COVID-19. For this reason, and...